Standout Papers

Cancer Immunoediting: Integrating Immun... 1990 2026 2002 2014 4.5k
  1. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion (2011)
    Robert D. Schreiber, Lloyd J. Old et al. Science
  2. Cancer immunoediting: from immunosurveillance to tumor escape (2002)
    Gavin P. Dunn, Allen T. Bruce et al. Nature Immunology
  3. Neoantigens in cancer immunotherapy (2015)
    Ton N. Schumacher, Robert D. Schreiber Science
  4. HOW CELLS RESPOND TO INTERFERONS (1998)
    George R. Stark, Ian M. Kerr et al. Annual Review of Biochemistry
  5. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death (1990)
    David M. Hockenbery, Gabriel Núñez et al. Nature
  6. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression (2015)
    Chih‐Hao Chang, Jing Qiu et al. Cell
  7. The Three Es of Cancer Immunoediting (2004)
    Gavin P. Dunn, Lloyd J. Old et al. Annual Review of Immunology
  8. The Immunobiology of Cancer Immunosurveillance and Immunoediting (2004)
    Gavin P. Dunn, Lloyd J. Old et al. Immunity
  9. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity (2001)
    Vijay Shankaran, Hiroaki Ikeda et al. Nature
  10. Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity (2008)
    Kai Hildner, Brian T. Edelson et al. Science
  11. Natural Innate and Adaptive Immunity to Cancer (2011)
    Matthew D. Vesely, Michael H. Kershaw et al. Annual Review of Immunology
  12. Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway (1996)
    Marco Antonio Meraz‐Ríos, J. Michael White et al. Cell
  13. Interferons, immunity and cancer immunoediting (2006)
    Gavin P. Dunn, Catherine Koebel et al. Nature reviews. Immunology
  14. The Molecular Cell Biology of Interferon-gamma and its Receptor (1993)
    Michael A. Farrar, Robert D. Schreiber Annual Review of Immunology
  15. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice (1998)
    Daniel H. Kaplan, Vijay Shankaran et al. Proceedings of the National Academy of Sciences
  16. New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape (2014)
    Deepak Mittal, Matthew M. Gubin et al. Current Opinion in Immunology
  17. Adaptive immunity maintains occult cancer in an equilibrium state (2007)
    Catherine Koebel, William Vermi et al. Nature
  18. Interferon-γ: the Major Mediator of Resistance Against Toxoplasma gondii (1988)
    Yasuhiro Suzuki, Manuel Orellana et al. Science
  19. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting (2012)
    Hirokazu Matsushita, Matthew D. Vesely et al. Nature
  20. Cytokine Signaling in 2002 (2002)
    John J. O’Shea, Massimo Gadina et al. Cell
  21. Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T Lymphocytes (1996)
    Luca G. Guidotti, Tetsuya Ishikawa et al. Immunity
  22. Type I interferon is selectively required by dendritic cells for immune rejection of tumors (2011)
    Mark S. Diamond, Michelle Kinder et al. The Journal of Experimental Medicine
  23. THE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor Signaling (1997)
    Erika A Bach, Michel Aguet et al. Annual Review of Immunology
  24. The roles of IFNγ in protection against tumor development and cancer immunoediting (2002)
    Hiroaki Ikeda, Lloyd J. Old et al. Cytokine & Growth Factor Reviews
  25. Recombinant IL-12 administration induces tumor regression in association with IFN- gamma production. (1994)
    Chet Nastala, Howard Edington et al. The Journal of Immunology
  26. Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses (1998)
    Scott J. Rodig, Marco Antonio Meraz‐Ríos et al. Cell
  27. Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity (2006)
    Mark J. Smyth, Gavin P. Dunn et al. Advances in immunology
  28. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. (1977)
    Michael K. Pangburn, Robert D. Schreiber et al. The Journal of Experimental Medicine
  29. Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling (2013)
    John R. Teijaro, Cherie Ng et al. Science
  30. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. (1995)
    Susanne J. Szabo, R Weber-Nordt et al. The Journal of Experimental Medicine
  31. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency (2003)
    Stéphanie Boisson‐Dupuis, Emmanuelle Jouanguy et al. Nature Genetics
  32. Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. (1982)
    D I Beller, Timothy A. Springer et al. The Journal of Experimental Medicine
  33. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice (1994)
    Sharon Erickson, Frédéric J. de Sauvage et al. Nature
  34. Tumor neoantigens: building a framework for personalized cancer immunotherapy (2015)
    Matthew M. Gubin, Maxim N. Artyomov et al. Journal of Clinical Investigation
  35. Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. (1985)
    N A Buchmeier, Robert D. Schreiber Proceedings of the National Academy of Sciences
  36. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity (2018)
    Elise Alspach, Danielle M. Lussier et al. Cold Spring Harbor Perspectives in Biology
  37. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity (2020)
    Stephen T. Ferris, Vivek Durai et al. Nature

Immediate Impact

42 by Nobel laureates 69 from Science/Nature 205 standout
Sub-graph 1 of 18

Citing Papers

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
19 intermediate papers

Works of Robert D. Schreiber being referenced

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Comparative Analysis of Regulatory and Effector T Cells in Progressively Growing versus Rejecting Tumors of Similar Origins
2006
and 16 more

Author Peers

Author Last Decade Papers Cites
Robert D. Schreiber 47711 33142 20381 378 78.3k
Gordon J. Freeman 53470 37868 14403 418 81.0k
Laurence Zitvogel 41768 30721 31005 488 77.2k
Tadamitsu Kishimoto 33603 25455 21971 633 76.3k
Drew M. Pardoll 46168 44257 23146 398 81.6k
Mark J. Smyth 52200 36937 19880 592 80.1k
Arlene H. Sharpe 47078 28206 16005 406 74.3k
Hideo Yagita∥ 43090 21401 18011 909 66.3k
Tasuku Honjo 39003 22887 24577 579 71.1k
Vijay K. Kuchroo 58286 20240 12985 424 77.7k
Tak W. Mak 33684 22375 49026 703 94.7k

All Works

Loading papers...

Rankless by CCL
2026